|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:approvalYear
|
2011
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L02BX03
|
|
gptkbp:brand
|
gptkb:Zytiga
|
|
gptkbp:CASNumber
|
154229-18-2
|
|
gptkbp:chemicalClass
|
gptkb:Corticosteroid
|
|
gptkbp:contraindication
|
pregnancy
|
|
gptkbp:developedBy
|
gptkb:Janssen_Biotech
|
|
gptkbp:discoveredBy
|
Institute of Cancer Research
|
|
gptkbp:eliminationHalfLife
|
12 ± 5 hours
|
|
gptkbp:hasMolecularFormula
|
C26H33NO2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
abiraterone acetate
|
|
gptkbp:indication
|
metastatic castration-resistant prostate cancer
metastatic high-risk castration-sensitive prostate cancer
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
CYP17A1 inhibitor
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:oftenGivenWith
|
gptkb:prednisone
|
|
gptkbp:patentExpired
|
2027 (US)
|
|
gptkbp:pregnancyCategory
|
gptkb:X_(US)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
edema
hypertension
hypokalemia
liver function abnormalities
|
|
gptkbp:synonym
|
17-(3-pyridyl)androsta-5,16-dien-3β-ol acetate
CB7630
|
|
gptkbp:usedFor
|
treatment of prostate cancer
|
|
gptkbp:bfsParent
|
gptkb:Yonsa
gptkb:Zytiga
|
|
gptkbp:bfsLayer
|
7
|